IOncology

The CheckMate 8HW trial, presented at the ASCO Gastrointestinal Cancers Symposium by Thierry Andre, is a randomized, multicenter, open-label phase 3 study evaluating the efficacy and safety of nivolumab (NIVO)…

The 2025 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU 2025) has already taken place in San Francisco, USA. This globally renowned academic event brought together top oncology scholars to jointly explore the cutting-edge breakthroughs and future directions in the field of genitourinary oncology.In this insightful exchange, Dr. Xuefeng Qiu from the Nanjing Drum Tower Hospital and Dr. Darren Poon from the Hong Kong Sanatorium and Hospital Comprehensive Cancer Center,China discuss key advances in mCRPC treatment, focusing on PARP inhibitors, ARPIs, and radioligand therapy. While genomic testing is shaping precision medicine, uncertainties remain regarding the benefit of PARP-ARPI combinations in ARPI-refractory patients. Dr. Poon highlights the potential of lutetium-177 PSMA therapy, especially for patients without prior chemotherapy.As precision oncology evolves, balancing efficacy, toxicity, and quality of life remains crucial. We appreciate our experts' insights and look forward to continued progress in prostate cancer treatment.

With the rapid advancement of ADC-based combination immunotherapies globally, the treatment landscape for advanced urothelial carcinoma has undergone a dramatic transformation, leading to multiple updates in clinical guidelines. This year’s ASCO Genitourinary Cancers Symposium (ASCO GU) was held from February 13–15 in San Francisco, where Professor Jun Guo from Peking University Cancer Hospital led a team of researchers. Professors Xinan Sheng and Bixia Tang presented two pivotal studies on Chinese innovative drugs for urothelial carcinoma, gaining international recognition.Urology Frontier invited the Peking University Cancer Hospital team to discuss key breakthroughs, ongoing challenges in the diagnosis and treatment of urothelial carcinoma, the results of the SHR-A2102 study, and the efficacy and patient benefits of RC48 in combination with toripalimab.

The MARGOT/TBCRC052 trial, presented at SABCS 2024, explored the efficacy of margetuximab + paclitaxel + pertuzumab (TMP) versus the standard trastuzumab + paclitaxel + pertuzumab (THP) in HER2+ stage II-III…

Prof. Nicholas Turner and colleagues presented findings from ZEST, the first Phase 3 trial evaluating MRD-guided therapy in breast cancer using circulating tumor DNA (ctDNA) surveillance.

At SABCS, Jean Wright presented a new analysis from the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 trials, providing critical insights into the role of tamoxifen for patients with "good risk"…

Prof. Sherko Kuemmel and the WSG Study Group presented key findings from the ADAPT HR+/HER2- chemotherapy trial, refining treatment strategies for high-risk HR+/HER2- early breast cancer.

The 2024 World Conference on Lung Cancer is happening in San Diego from September 7th to 10th! The WCLC website has already released some groundbreaking abstracts. Here are the key…

The 2024 World Conference on Lung Cancer is happening in San Diego from September 7th to 10th! The WCLC website has already released important abstracts. Below are some key research…

The 2024 World Conference on Lung Cancer is taking place in San Diego from September 7th to 10th! Some key abstracts have already been released. Here’s an overview of the…